lurasidone


SMILES O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1
InChIKey PQXKDMSYBGKCJA-CVTJIBDQSA-N

Chemical properties

Hydrogen bond acceptors 6
Hydrogen bond donors 0
Rotatable bonds 5
Molecular weight (Da) 492.3

Drug properties

Molecular type Small molecule
Physiological/Surrogate Surrogate
Approved drug Yes

Database connections

Sankey plot

Bioactivities

Receptor Activity Source
GTP Uniprot Species Family Class Type Min Avg Max Database
5-HT7 5HT7R Human 5-Hydroxytryptamine A pKi 9.31 9.31 9.31 Guide to Pharmacology
α2A ADA2A Human Adrenoceptors A pKi 6.7 7.05 7.4 Guide to Pharmacology
α2C ADA2C Human Adrenoceptors A pKi 7.3 7.65 8.0 Guide to Pharmacology
5-HT2A 5HT2A Rat 5-Hydroxytryptamine A pKi 8.69 8.69 8.69 Guide to Pharmacology
5-HT1A 5HT1A Rat 5-Hydroxytryptamine A pKi 8.17 8.17 8.17 Guide to Pharmacology
D2 DRD2 Rat Dopamine A pKi 8.77 8.77 8.77 Guide to Pharmacology
5-HT7 5HT7R Human 5-Hydroxytryptamine A pKi 9.3 9.3 9.3 ChEMBL
D2 DRD2 Rat Dopamine A pKi 8.78 8.78 8.78 ChEMBL
5-HT1A 5HT1A Rat 5-Hydroxytryptamine A pKi 8.17 8.17 8.17 ChEMBL
5-HT2A 5HT2A Human 5-Hydroxytryptamine A pKi 8.7 8.7 8.7 ChEMBL
5-HT1A 5HT1A Human 5-Hydroxytryptamine A pKi 8.17 8.17 8.17 ChEMBL
D2 DRD2 Human Dopamine A pKi 8.77 8.77 8.77 ChEMBL
5-HT1A 5HT1A Human 5-Hydroxytryptamine A pKi 8.09 8.09 8.09 Drug Central
5-HT2A 5HT2A Human 5-Hydroxytryptamine A pKi 8.03 8.03 8.03 Drug Central
5-HT7 5HT7R Human 5-Hydroxytryptamine A pKi 8.03 8.03 8.03 Drug Central
α2A ADA2A Human Adrenoceptors A pKi 8.13 8.13 8.13 Drug Central
α2C ADA2C Human Adrenoceptors A pKi 8.1 8.1 8.1 Drug Central
D2 DRD2 Human Dopamine A pKi 8.05 8.05 8.05 Drug Central
5-HT2A 5HT2A Rat 5-Hydroxytryptamine A pKi 8.06 8.06 8.06 Drug Central
5-HT1A 5HT1A Rat 5-Hydroxytryptamine A pKi 8.09 8.09 8.09 Drug Central
D2 DRD2 Rat Dopamine A pKi 8.06 8.06 8.06 Drug Central
Receptor Activity Source
GTP Uniprot Species Family Class Type Min Avg Max Database
5-HT7 5HT7R Human 5-Hydroxytryptamine A pIC50 7.8 7.8 7.8 ChEMBL